Analysis group,Analysis number,Subgroup,Subgroup number,Experimental cases,Experimental N,Control cases,Control N,Weight,Mean,CI start,CI end,Heterogeneity Tau²,Tau² CI start,Tau² CI end,Heterogeneity Chi²,Heterogeneity df,Heterogeneity P,Heterogeneity I²,Effect Z,Effect T,Effect P,ID
2,1,Degarelix 240 mg/80 mg,1,48,732,80,734,40.953958,0.66321,0.38739,1.135412,0.152905,,,9.05188,6,0.170681,33.715427,1.497018,,0.134388,subgroup:459621000464490037
2,1,Degarelix 240 mg/160 mg,2,24,202,28,201,19.14312,0.8529,0.512652,1.41897,0.0,,,0.0,0,1.0,0.0,0.612631,,0.540121,subgroup:459621000466062909
2,1,Degarelix 240 mg/480 mg,3,73,682,49,400,39.902921,0.895633,0.635391,1.262466,0.0,,,0.025643,1,0.872776,0.0,0.629307,,0.529148,subgroup:459621000466325055
2,2,Degarelix 240 mg/80 mg,1,,976,,1064,63.96366,-0.027369,-0.332212,0.277473,0.03572,,,3.140901,1,0.076352,68.162007,0.175969,,0.860318,subgroup:459621000467111491
2,2,Degarelix 240 mg/480 mg,2,,565,,282,36.03634,0.099583,-0.043399,0.242565,0.0,,,0.0,0,1.0,0.0,1.365062,,0.172233,subgroup:459621000467635782
2,3,Degarelix 240 mg/80 mg,1,200,691,22,595,58.83112,14.937134,4.479684,49.806628,1.287923,,,13.986554,5,0.015695,64.251379,4.400448,,1.1E-5,subgroup:459621000467897929
2,3,Degarelix 240 mg/160 mg,2,61,202,0,100,5.554524,61.197044,3.824005,979.360109,0.0,,,0.0,0,1.0,0.0,2.908066,,0.003637,subgroup:459621000468946512
2,3,Degarelix 240 mg/480 mg,3,261,682,11,400,35.614357,15.240423,8.503752,27.313885,0.0,,,0.835387,1,0.360719,0.0,9.150574,,0.0,subgroup:459621000469732946
